New Data Reshape Nonstatin Lipid Therapy Choices
Kelsey Norman, PharmD, discussed new data and guidelines reshaping hyperlipidemia management at the NEIAP 2026 Annual Forum. She highlighted the role of pharmacists in optimizing lipid-lowering therapies, including PCSK9 inhibitors, ezetimibe, and bempedoic acid. Norman noted the FDA's expanded indication for evolocumab (Repatha; Amgen) based on the VESALIUS-CV trial, and the missed primary endpoint in the Lp(a)HORIZON trial (NCT04023552) for pelacarsen (Novartis).
How this was made
The 30-second read
Why it matters
The article introduces fresh FDA‑expanded indication for evolocumab and a failed Lp(a) trial, shaping therapeutic choices.
Market read
New clinical data may re‑price PCSK9 inhibitors and influence pharmacist‑driven prescribing.
What to watch
Reimbursement and access barriers for injectables could temper demand despite positive trial outcomes.
Background
Pharmacy Times interview with a clinical pharmacist discussing new lipid‑lowering trial data and evolving guideline roles.
Ticker impact
FDA expands evolocumab indication after VESALIUS-CV trial showing primary‑prevention benefit.
likely upward pressure as market prices in expanded use.
New primary‑prevention evidence differentiates evolocumab from peers.
Alirocumab lacks primary‑prevention data; only secondary‑prevention evidence cited.
potential modest pressure if investors shift to evolocumab.
No fresh trial boost; competitive disadvantage highlighted.
Ezetimibe (Zetia) mentioned as a cost‑effective option in triple‑therapy regimens.
little immediate impact.
Article discusses cost parity, not a catalyst.
Pelacarsen trial missed primary endpoint; Novartis' Lp(a) program noted.
potential short‑term pressure.
First report of missed endpoint for a high‑profile asset.
Market effects
Highlights growing role of PCSK9 inhibitors and triple‑therapy regimens in hyperlipidemia management.
U.S. lipid‑therapy market may see shift toward agents with primary‑prevention data.
International guidelines now cite pharmacists, potentially expanding prescribing pathways worldwide.
Counterpoint
Investors may view the lack of new data for alirocumab and bempedoic acid as a sign of limited upside.
Key entities
- companyAmgen
Manufacturer of evolocumab (Repatha).
- companyNovartis
Developer of pelacarsen, Lp(a) therapy.
